Latest News and Press Releases

Mainz Biomed Announces Registration of ColoAlert in the United Kingdom

Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®

Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants

Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies

MYNZ Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition

Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test

Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants

Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study

Mainz Biomed Enters into Technology Partnership with EDX Medical Group